Stanislas MALMEZAT

Stanislas MALMEZAT has a wealth of experience in the financial and biotech sectors. Stanislas began their career in 2004 as a Product Manager Trainee in Marketing at Janssen-Cilag. In 2005, they became an Analyst Trainee in a Venture Capital Fund at Innoven-Partners. In 2006, they moved to Ernst & Young as a Senior Analyst in Transaction Advisory Services. In 2008, they joined Duff & Phelps as a Senior Associate. In 2011, they became the Chief Financial Officer in Diagnostics at Rarecells Diagnostics. In 2013, they joined Clevexel Pharma as a Board Member and Chief Financial Officer in Biotech and Life Sciences. Finally, in 2018, they became the Chief Financial Officer in Biotech, Drug Discovery, and Clinical Development at DOMAIN Therapeutics.

Stanislas Malmezat obtained a PharmD from the School of Pharmacy in 1998-2004. Stanislas then attended IAE Caen in 2002-2003, where they obtained a MAE (ex CAAE) - Master professionnel d'Administration des Entreprises. In 2003-2006, they attended ESSEC Business School and obtained an MBA (Pg - Grande Ecole). In 2005, they were an Exchange Student at Duke University - The Fuqua School of Business, also for an MBA.